Rhumbline Advisers bought a new stake in Grail, Inc. (NASDAQ:GRAL - Free Report) during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The firm bought 25,539 shares of the company's stock, valued at approximately $456,000. Rhumbline Advisers owned about 0.08% of Grail at the end of the most recent quarter.
Other institutional investors have also modified their holdings of the company. C2P Capital Advisory Group LLC d.b.a. Prosperity Capital Advisors acquired a new stake in Grail in the fourth quarter valued at about $244,000. Moloney Securities Asset Management LLC acquired a new stake in shares of Grail in the 4th quarter valued at approximately $559,000. Wesbanco Bank Inc. purchased a new stake in shares of Grail in the fourth quarter valued at approximately $523,000. Slow Capital Inc. purchased a new stake in shares of Grail in the fourth quarter valued at approximately $2,379,000. Finally, abrdn plc acquired a new position in Grail during the fourth quarter worth $3,768,000.
Wall Street Analyst Weigh In
Several equities research analysts have commented on the stock. Morgan Stanley began coverage on shares of Grail in a research report on Wednesday, November 27th. They set an "equal weight" rating and a $16.00 target price on the stock. Wolfe Research initiated coverage on shares of Grail in a report on Friday, November 15th. They set a "peer perform" rating on the stock.
Check Out Our Latest Stock Analysis on Grail
Grail Stock Performance
NASDAQ GRAL traded up $0.10 during mid-day trading on Wednesday, hitting $30.64. The stock had a trading volume of 1,097,976 shares, compared to its average volume of 1,559,382. The company has a 50 day simple moving average of $31.16 and a 200 day simple moving average of $21.08. Grail, Inc. has a 52-week low of $12.33 and a 52-week high of $63.99.
Grail (NASDAQ:GRAL - Get Free Report) last released its quarterly earnings results on Thursday, February 20th. The company reported ($1.86) earnings per share (EPS) for the quarter, topping the consensus estimate of ($4.41) by $2.55. The firm had revenue of $38.25 million for the quarter, compared to analyst estimates of $35.33 million. Sell-side analysts expect that Grail, Inc. will post -15.15 EPS for the current fiscal year.
Grail Profile
(
Free Report)
GRAIL, Inc is a healthcare company. It engages in the development of a technology for early detection of cancer. The company was founded by Jeffrey T. Huber, William H. Rastetter, and Mostafa Ronaghi on September 11, 2015 and is headquartered in Menlo Park, CA.
Featured Stories
Before you consider Grail, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Grail wasn't on the list.
While Grail currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
